have developed using Apple's ResearchKit framework. Our goal is to enroll 3000 patients with claudication (Rutherford 1-3) and healthy controls. The app enables data collection from patients all across the United States. This trial is Institutional Review Board approved, and all activities (registration, consent, and data gathering) are performed on the phone. Two main types of data are collected: medical/surgical history and physical activity data. Medical/surgical history is obtained through simple surveys that gather information on cardiovascular risk factors, symptoms, medications, and previous surgical procedures. Physical activity data consists of active and passive components. For the active component, patients get notifications to perform biweekly 6-minute walk tests, which have previously been validated for use on smartphones. For the passive component, the app will record (1) daily total steps walked, (2) total distance walked per day, (3) total flights climbed per day, and (4) maximum steps without stopping per day. This is an algorithm we developed. The  Fig presents a summary of the study design. Validation of mobile phone activity monitoring for PAD patients will be done through cluster analysis of all variables measured as well as analysis of variance analysis of PAD vs non-PAD patients. Subanalysis of patients who undergo endovascular or open procedures will be performed to report on actual changes in activity levels postprocedure as well as durability of procedures on activity.
Objectives: Patient-centered care is widely championed but challenging to implement. A key ingredient to patient-centered care is understanding the patient's perspective, including which problems need to be addressed and what needs must be met. We conducted a prospective focus group study of patients with symptomatic peripheral artery disease (PAD) to explore factors patients consider most important about their treatment, compare values and perceptions between patients, and characterize terms that patients use when communicating about their symptoms and treatment.
Methods: Patients with ankle-brachial (ABI) <.9 and a diagnosis of symptomatic PAD (either critical limb ischemia [CLI] or intermittent claudication [IC]) were recruited. Moderated focus groups separated by diagnosis (either CLI or IC) explored factors important for decision making. Verbatim transcripts were imported into a quantitative analysis program. Analysis included identification of themes using word frequency, coding, exploration of hierarchies and interactions, and screening for emergent (latent) classes. Interactions were evaluated using matrix coding queries and quantified based on percent coverage. Hierarchical associations and linkages between attributes will be explored graphically using tree map charts and cluster analysis.
Results: Focus groups included 51 participants (26 CLI and 25 IC). Mean age was 67 6 13, and mean ABI was 0.52 6 0.16. Factors considered important for treatment choices varied considerably by diagnosis and between individuals (Fig) . Some expressed negative attitudes toward pharmacotherapy and exercise therapy, regarding them as barriers or delay tactics (rather than alternatives) to revascularization, while others expressed strong preferences to avoid procedures if possible. Durability, risk, and invasiveness were consistently important but often prioritized differently by people with similar disease severity. Some were willing to accept increased risk or invasiveness if better symptomatic responses or more durable results were possible, while others preferred less invasive treatments regardless of these considerations. Recovery, cosmetic outcomes, degree of symptomatic response, and test/diagnosis reliability were factors mentioned by participants with IC but not CLI. Participants often used conceptually accurate terms but sometimes also used terms that were incorrect or inconsistent with medical terminology. Symptoms were discussed in both literal and metaphorical terms. Participants used some terms to inclusively describe both endovascular and surgical procedures, while other terms more consistently associated with a specific revascularization approach. No statistically significant differences (P < .05).
Fig.
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Conclusions: Many factors that patients with symptomatic PAD consider important and terms that they use to communicate are absent from consensus treatment guidelines. Areas of mismatch between patientand clinician-defined decision approaches and terminology represent opportunities for development of more patient-centered approaches to care and communication. Objectives: This study retrospectively created a predictive score for primary patency (PP) in patients with critical limb ischemia (CLI) operated on with the use of a heparin-bonded expanded polytetrafluoroethylene (ePTFE) bypass graft (Hb-ePTFE) in a large multicenter registry.
Methods: Over a 13-year period, ending in December 2014, a Hb-ePTFE graft was implanted in 683 patients undergoing below-knee revascularization for CLI in seven Italian vascular hospitals. Data concerning these interventions were retrospectively collected in a multicenter registry with a dedicated database. Follow-up results were analyzed in terms of PP: univariate and multivariable analyses with Kaplan-Meier estimates were used to identify potential significant predictors of such end point at 3 years, and then a predictive risk score was constructed by dividing the b-coefficient of each significant predictor at multivariable analysis by 0.25 and by rounding off to the nearest integer value. A qualitative assessment of the Kaplan-Meier survival estimates for each integer score was performed, and subgroups of risk were stratified on the basis of the primary end point. Comparison between subgroups was performed with log-rank test.
Results: Median duration of follow-up was 34 months (range, 1-123; standard deviation, 27.8 months). Overall, estimated 3-year PP rate was 51.3% (standard error, 0.02). At multivariate analysis, female gender, reintervention following the failure of previous open or endovascular intervention, and the need for distal tibial anastomosis were predictors of poorer PP. The integer score ranged from 0 to 6. Kaplan-Meier analysis for PP in each score group identified four subgroups with significant differences at 3 years: score 0 (PP, 63%), score 2 (PP, 49%; P ¼ .003, log-rank 6.1, in comparison with score 0), score 4 (PP, 39%; P ¼ .05, log-rank 2.2, in comparison with score 2), and score 6 (PP, 25%; P ¼ . 01, log-rank 2.7 in comparison with score 4).
Conclusions: A category of patients with CLI treated with the indexed graft with excellent patency rates does exist, thus suggesting a primary role for Hb-ePTFE in such patients. A prospective validation of such a score is necessary.
Author Disclosures: P. Castelli: Nothing to disclose; W. Dorigo: Nothing to disclose; P. Ottavi: Nothing to disclose; G. Piffaretti: Nothing to disclose; C. Pratesi: Nothing to disclose; R. Pulli: Nothing to disclose.
IP231. Kidney Transplant Increases the Risk of Ipsilateral Critical Limb Ischemia
Ziad Al Adas, Timothy Nypaver, Alex D. Shepard, Mitchell R. Weaver, Lauren Malinzak, Naushaba Khalid, Anita Patel, Loay Kabbani. Henry Ford Health System, Detroit, Mich
Objectives: End-stage renal disease is a known risk factor for peripheral arterial disease (PAD). Hypertension, hyperlipidemia, and diabetes, which are highly prevalent in renal transplant candidates, are independent risk factors for atherosclerosis and PAD. Renal transplantation is an invasive arterial procedure that may have effects on ipsilateral limb perfusion and/or progression of atherosclerotic disease. We hypothesized that the lower extremity ipsilateral to the side of the kidney transplant may be at increased risk for PAD complications.
Methods: Our transplant database was retrospectively queried for all kidney transplant patients who underwent subsequent lower extremity revascularization or amputation procedures. Patients with concomitant pancreatic transplants or bilateral renal transplants were excluded. Patient demographics, comorbidities, and discharge medications were collected, and data analysis was conducted on SPSS 22.0 software (IBM Corp, Armonk, NY).
Results: Between January 2004 and August 2016, 1214 patients received a renal transplant at our tertiary referral center. Of these, 25 patients (2%) had subsequent arterial revascularizations or amputations on either lower extremity. Average age was 55 years; 76% were male, 65% were African American, 92% had diabetes, 92% had hypertension, 44% had a history of coronary artery disease, and 72% were on aspirin or another antiplatelet agent. Eighteen patients had lower extremity vascular interventions (13 amputations and 5 revascularizations) ipsilateral to the transplanted kidney, and seven patients had contralateral vascular interventions (all amputations; P ¼ .043). The average interval between transplantation and subsequent vascular intervention was 27 months for the ipsilateral interventions and 39 months for the contralateral interventions (P ¼ .37).
Conclusions: Kidney transplantation is associated with an increased risk of ipsilateral lower extremity PAD requiring surgical intervention. Further studies are necessary to determine whether this represents a "steal" phenomenon vs progression of atherosclerosis distal to the transplanted kidney. Renal transplant patients should be monitored closely for the development of ischemic symptoms in the lower extremity ipsilateral to the transplanted kidney.
Author Disclosures: Z. Al Adas: Nothing to disclose; L. Kabbani: Nothing to disclose; N. Khalid: Nothing to disclose; L. Malinzak: Nothing to disclose; T. Nypaver: Nothing to disclose; A. Patel: Nothing to disclose; A. D. Shepard: Nothing to disclose; M. R. Weaver: Nothing to disclose.
IP233.
Hybrid Approach for Aortoiliac TASC C and D Lesions
Paola Wiesel, Noemi Ventrella, Michele Tedesco, Giovanni Mastrangelo, Domenico Angiletta, Raffaele Pulli. University of Bari, Bari, Italy
Objectives: The recommended treatment of TASC (TransAtlantic InterSociety Consensus II) C and D iliac and femoral atherosclerotic disease is an open surgical approach, although in the last few years endovascular treatment is increasing. We hypothesized that a hybrid approach, combining iliac endovascular revascularization with common femoral artery endarterectomy, may improve long-term patency compared with angioplasty and stenting or with endarterectomy alone, reducing the morbidity rate.
Methods: We reviewed our clinical series of patients who underwent an endovascular or hybrid treatment from June 2015 to October 2016 for occlusive aortoiliac disease. Patient demographics, comorbidities, operative details, and risk factors were analyzed. Early and midterm results (12 months) were recorded in terms of primary and secondary patency, amputation, and survival. All patients underwent a double-antiplatelet therapy or anticoagulation combined with one antiplatelet drug. Immediate data were analyzed using the c 2 test, and the longterm results were analyzed using the Kaplan-Meyer curve and the logrank test.
Results: During the index period, 37 patients with aortoiliac and femoral disease were treated: 25 (67.6%) underwent an endovascular treatment (group 1) and 12 (32.4%) a hybrid approach (group 2). TASC lesions were divided in 37% of C and 63% of D. In eight patients (20% endovascular and 25% hybrid) we performed a kissing stent of CIA, and nine patients (20% endovascular and 33.3% hybrid) also had a FSA percutaneous transluminal angioplasty. In only seven patients, all of them in the group 1, we performed a plane angioplasty, whereas in the remaining 30, we positioned 38 stents, 15 of them were covered stents and 23 were bare-metal stents. No intraoperative complications occurred. In group 1, three patients required an additional endovascular procedure for an early thrombosis,
